 DEVON, Pa., Sept. 09, 2021 GLOBE NEWSWIRE -- Zynerba Pharmaceuticals, Inc. Nasdaq: ZYNE, the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2 BRIGHT trial describing tolerability and efficacy of Zygel cannabidiol formulated in a transdermal gel ZYN002 in children and adolescents with autism spectrum disorder ASD over a longer term, 38-week treatment period. These data were presented as an oral presentation at The Society for the Study of Behavioural Phenotypes SSBP Conference 2021 being held virtually from September 9-10, 2021. A copy of the presentation is available on the Zynerba corporate website at 